PORTABLE MEDICAL TREATMENT SYSTEM AND METHOD OF USE
A medical treatment system including a treatment chamber, a source of an aqueous mist containing a medication, a source of an oxygen-enriched gas, and a control system adapted to alternately surround a human body part with a mist containing a medication and the oxygen enriched gas, which can be used to treat various skin disorders including infected lesions, bacterial infections such as acne (i.e. Propionibacterium acnes ), fungal infections such as Athlete's foot (i.e. fungal genus Trichophyton ), conditions associated with hair loss including alopecia as well as ulcerations and frostbite resulting from poor circulation. A method of treating skin disorders is also disclosed, that includes providing a mist containing a medication and enriched oxygen gas to the site being treated as well as providing oxygen to the patient during treatment.
1 - 17 . (canceled)
18 . A method for treating a wound, comprising: (a) covering said wound with a treatment chamber; (b) surrounding said wound in said treatment chamber with a vapor containing water and/or a medicament; and (c) surrounding said wound in said treatment chamber with an 02-enriched gas without increasing the pressure around the wound to 22 mm Hg wherein said vapor and said 02-enriched gas is prepared using a portable variable hyperoxia treatment apparatus having a housing containing a first, a second and a third sealable chambers, said first sealable chamber for housing an energy source, said second sealable chamber for receiving a cartridge containing water or a medicament, said third chamber for receiving a gas containing cartridge, each chamber having a top and bottom ends, a programmable control circuit powered by an energy source, said energy source to be housed in said first sealable chamber, a humidifier electronically connected to said top end of said second chamber and in contact with said water or medicament, a flow control regulator on the top end of said third chamber connected to said control circuit for dispensing gas from said gas containing cartridge, a storage port above said humidifier for humidified vapor or medicament, a main valve controlled by said control circuit and connected to said storage port and said flow control regulator, an exit port connected to said main valve for dispensing said humidified vapor or medicament and/or gas and a sealable cap for each of said three sealable chambers.
19 . The method according to claim 18 , wherein said wound is a surgical incision.
20 . The method according to claim 18 , wherein said wound is a chronic lesion.
21 . The method according to claim 18 , wherein said wound is a post-surgical infection, a gangrenous lesion, a decubitus ulcer, or a venous stasis.
22 . The method according to claim 18 , wherein said wound is a skin ulceration resulting from an amputation, skin graft, burn or frostbite.
23 . The method according to claim 18 , wherein said medicament is an antibiotic or further comprises an antibiotic.
24 . The method according to claim 18 , wherein said antibiotic is selected from the group of betadine, isopropyl alcohol, bacitracin, hydrogen peroxide, and combinations thereof.
25 . The method according to claim 18 , wherein said antibiotic is ionic silver.
26 . The method according to claim 18 , wherein said wound is the result of bacterial or fungal infection.
27 . The method according to claim 26 , wherein said bacterial infection is acne.
28 . The method according to claim 27 , wherein said acne is Propionibacterium acnes.
29 . The method according to claim 18 , wherein said medicament is benzoyl peroxide, salicylic acid, glycolic acid, sulfur or azelaic acid.
30 . The method according to claim 26 , wherein said fungal infection is Athlete's foot.
31 . The method according to claim 26 , wherein said fungal infection is cause by a fungus of the genus Trichophyton.
32 . The method according to claim 18 , wherein said medicament is (RS)-1-(2-(2,4-Dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl)-1H-imidazole (Miconazole™), 1-[(2-chlorophenyl)(diphenyl)methyl]-1H-imidazole (Clotrimazole™), [(2E)-6,6-dimethylhept-2-en-4-yn-1-yl](methyl)(naphthalen-1-ylmethyl)amine (Terbinafine™), O-2-naphthyl methyl(3-methylphenyl)thiocarbamate (Tolnaftate™) or [(4-tert-butylphenyl)methyl](methyl)(naphthalen-1-ylmethyl)amine (Butenafine™).
33 . The method according to claim 18 , wherein said 02-enriched gas is substantially pure 02.
34 . The method according to claim 18 , wherein steps (b) and (c) are performed simultaneously one or more times in a single treatment.
35 . The method according to claim 18 , wherein steps (b) and (c) are performed sequentially one or more times in a single treatment.
36 . The method according to claim 18 , wherein steps (b) and (c) are performed simultaneously for about 2 to about 30 minutes.
37 . The method according to claim 18 , wherein steps (b) and (c) are performed simultaneously for about 15 minutes.
38 - 55 . (canceled)